Projects

Besides our service offers, Red Glead Discovery has a couple of early R&D projects with partners with complementary skills. If you want to know more about our on-going projects or want to discuss how we may be a partner for your project, please contact us.

 

Red Glead Discovery currently pursues drug discovery in three therapy areas together with different partners. The project "Nile" is an on-going in-house effort employing fragment-based lead discovery to find novel compounds for an epigenetic target for the treatment of cancer. This project is a collaboration between Red Glead Discovery, SARomics Biostructures and the research group of Jonas Nilsson at Sahlgrenska Hospital (Gothenburg, Sweden) and has recently received a research grant from Vinnova (the Swedish innovation agency).

The two other projects have been spun out into separate companies:

  • Apoglyx AB develops a novel therapeutic concept for the treatment of hyperglycemia in patients with diabetes mellitus type 2.
  • Merozyne Therapeutics AB aims at bringing relief to patients with the rare condition laminin alpha2 chain-deficient congenital muscular dystrophy (MDC1A), by developing a small- molecule based treatment for this orphan disease.

Please have a look at the respective webpage of Apoglyx and Merozyne to get further information on these projects.

 

Contact

+46 46 460 12 90
+46 46 460 12 91
+46 46 460 12 92
info@redglead.com

Visiting address

Medicon Village
Building 403
Scheelevägen 2
223 63 Lund, Sweden

Shipping address

Red Glead Discovery AB
Medicon Village
Scheelevägen 8
223 63 Lund, Sweden

Postal address

Medicon Village
SE-223 81 Lund, Sweden